305 related articles for article (PubMed ID: 26799184)
1. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
2. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
3. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.
Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW
Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833
[TBL] [Abstract][Full Text] [Related]
4. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
5. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
7. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
[TBL] [Abstract][Full Text] [Related]
8. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
9. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.
Delogu S; Wang C; Cigliano A; Utpatel K; Sini M; Longerich T; Waldburger N; Breuhahn K; Jiang L; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
Oncotarget; 2015 Feb; 6(4):2222-34. PubMed ID: 25537506
[TBL] [Abstract][Full Text] [Related]
10. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
12. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
14. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
[TBL] [Abstract][Full Text] [Related]
15. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
16. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
17. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
[TBL] [Abstract][Full Text] [Related]
18. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
20. A model for RAS mutation patterns in cancers: finding the sweet spot.
Li S; Balmain A; Counter CM
Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
